{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/managing-hematological-cancers-peer-reviewed-journal-article-featuring-fortrea-oncologists#webpage",
"url": "https://www.fortrea.com/insights/managing-hematological-cancers-peer-reviewed-journal-article-featuring-fortrea-oncologists",
"name": "Managing Hematological Cancers: Peer-reviewed Journal Article Featuring Fortrea Oncologists",
"description": "This Fortrea infosheet explores how hematological cancers are being addressed through precision medicine, translational hematology research, and evolving oncology clinical development strategies. The content focuses on scientific and clinical perspectives related to genomic biomarkers, personalized treatment approaches, oncology evidence generation, and emerging therapeutic strategies across blood cancer research and treatment environments. The infosheet highlights how precision medicine is increasingly influencing hematologic oncology through biomarker-driven research, translational scientific insights, and individualized treatment planning designed to support targeted therapeutic decision-making. Fortrea oncologists discuss ongoing developments in hematological cancer clinical development, translational research integration, and precision medicine approaches that are shaping future blood cancer treatment strategies and oncology innovation. By integrating oncology evidence generation with translational hematology research and precision medicine insights, the infosheet provides a broader understanding of current trends influencing hematological cancer treatment and clinical development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Managing Hematological Cancers: Peer-reviewed Journal Article Featuring Fortrea Oncologists",
"item": "https://www.fortrea.com/insights/managing-hematological-cancers-peer-reviewed-journal-article-featuring-fortrea-oncologists"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/managing-hematological-cancers-peer-reviewed-journal-article-featuring-fortrea-oncologists#infosheet",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/managing-hematological-cancers-peer-reviewed-journal-article-featuring-fortrea-oncologists#webpage"
},
"headline": "Hematological Cancers: Precision Medicine and Emerging Treatment Insights | Fortrea Infosheet",
"description": "This Fortrea infosheet explores how hematological cancers are being addressed through precision medicine, translational hematology research, and evolving oncology clinical development strategies. The content focuses on scientific and clinical perspectives related to genomic biomarkers, personalized treatment approaches, oncology evidence generation, and emerging therapeutic strategies across blood cancer research and treatment environments. The infosheet highlights how precision medicine is increasingly influencing hematologic oncology through biomarker-driven research, translational scientific insights, and individualized treatment planning designed to support targeted therapeutic decision-making. Fortrea oncologists discuss ongoing developments in hematological cancer clinical development, translational research integration, and precision medicine approaches that are shaping future blood cancer treatment strategies and oncology innovation. By integrating oncology evidence generation with translational hematology research and precision medicine insights, the infosheet provides a broader understanding of current trends influencing hematological cancer treatment and clinical development.",
"genre": "Info Sheet",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-07-12",
"dateModified": "2025-07-12",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-07/hematological-cancers-peer-reviewed-fortrea-oncologists.pdf",
"encodingFormat": "application/pdf"
}
}
]
}